danaher corp. - DHR
DHR
Close Chg Chg %
190.64 -3.71 -1.95%
Closed Market
186.93
-3.71 (1.95%)
Volume: 3.67M
Last Updated:
Apr 17, 2025, 3:59 PM EDT
Company Overview: danaher corp. - DHR
DHR Key Data
| Open $188.99 | Day Range 185.83 - 189.54 |
| 52 Week Range 171.01 - 281.70 | Market Cap $133.67B |
| Shares Outstanding 715.45M | Public Float 648.54M |
| Beta 0.87 | Rev. Per Employee N/A |
| P/E Ratio 35.32 | EPS $5.33 |
| Yield 60.48% | Dividend $0.32 |
| EX-DIVIDEND DATE Mar 28, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 4.39M |
DHR Performance
| 1 Week | -1.01% | ||
| 1 Month | -11.61% | ||
| 3 Months | -21.62% | ||
| 1 Year | -20.67% | ||
| 5 Years | 35.20% |
DHR Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
30
Full Ratings ➔
About danaher corp. - DHR
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.
DHR At a Glance
Danaher Corp.
2200 Pennsylvania Avenue North West
Washington, District of Columbia 20037-1701
| Phone | 1-202-828-0850 | Revenue | 23.88B | |
| Industry | Miscellaneous Commercial Services | Net Income | 3.90B | |
| Sector | Commercial Services | Employees | 63,000 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
DHR Valuation
| P/E Current | 35.325 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 43.402 |
| Price to Sales Ratio | 7.088 |
| Price to Book Ratio | 3.332 |
| Price to Cash Flow Ratio | 25.303 |
| Enterprise Value to EBITDA | 24.456 |
| Enterprise Value to Sales | 7.719 |
| Total Debt to Enterprise Value | 0.093 |
DHR Efficiency
| Revenue/Employee | 378,968.254 |
| Income Per Employee | 61,888.889 |
| Receivables Turnover | 5.438 |
| Total Asset Turnover | 0.295 |
DHR Liquidity
| Current Ratio | 1.397 |
| Quick Ratio | 1.054 |
| Cash Ratio | 0.306 |
DHR Profitability
| Gross Margin | 59.502 |
| Operating Margin | 21.713 |
| Pretax Margin | 19.46 |
| Net Margin | 16.331 |
| Return on Assets | 4.813 |
| Return on Equity | 7.569 |
| Return on Total Capital | 5.847 |
| Return on Invested Capital | 5.685 |
DHR Capital Structure
| Total Debt to Total Equity | 34.608 |
| Total Debt to Total Capital | 25.71 |
| Total Debt to Total Assets | 22.112 |
| Long-Term Debt to Equity | 33.24 |
| Long-Term Debt to Total Capital | 24.694 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Danaher Corp. - DHR
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 29.45B | 31.47B | 23.89B | 23.88B | |
Sales Growth
| +32.17% | +6.85% | -24.09% | -0.06% | |
Cost of Goods Sold (COGS) incl D&A
| 11.50B | 12.52B | 9.86B | 9.67B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.17B | 2.22B | 2.17B | 2.35B | |
Depreciation
| 718.00M | 738.00M | 675.00M | 721.00M | |
Amortization of Intangibles
| 1.45B | 1.48B | 1.49B | 1.63B | |
COGS Growth
| +17.25% | +8.88% | -21.29% | -1.90% | |
Gross Income
| 17.95B | 18.95B | 14.03B | 14.21B | |
Gross Income Growth
| +43.90% | +5.55% | -25.94% | +1.23% | |
Gross Profit Margin
| +60.95% | +60.21% | +58.74% | +59.50% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 9.90B | 10.25B | 8.76B | 9.02B | |
Research & Development
| 1.74B | 1.75B | 1.50B | 1.58B | |
Other SG&A
| 8.16B | 8.51B | 7.25B | 7.44B | |
SGA Growth
| +21.30% | +3.53% | -14.60% | +3.05% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 400.00M | 403.00M | 348.00M | 534.00M | |
EBIT after Unusual Expense
| 7.65B | 8.29B | 4.93B | 4.65B | |
Non Operating Income/Expense
| 189.00M | 212.00M | 402.00M | 274.00M | |
Non-Operating Interest Income
| 11.00M | 41.00M | 303.00M | 117.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 241.00M | 214.00M | 289.00M | 278.00M | |
Interest Expense Growth
| -11.72% | -11.20% | +35.05% | -3.81% | |
Gross Interest Expense
| 241.00M | 214.00M | 289.00M | 278.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 7.60B | 8.29B | 5.04B | 4.65B | |
Pretax Income Growth
| +69.03% | +9.13% | -39.17% | -7.89% | |
Pretax Margin
| +25.80% | +26.35% | +21.11% | +19.46% | |
Income Tax
| 1.25B | 1.08B | 823.00M | 747.00M | |
Income Tax - Current - Domestic
| 346.00M | 413.00M | 756.00M | 301.00M | |
Income Tax - Current - Foreign
| 1.13B | 1.23B | 1.27B | 929.00M | |
Income Tax - Deferred - Domestic
| (206.00M) | (400.00M) | (866.00M) | (342.00M) | |
Income Tax - Deferred - Foreign
| (23.00M) | (159.00M) | (338.00M) | (141.00M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 6.35B | 7.21B | 4.22B | 3.90B | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 6.35B | 7.21B | 4.22B | 3.90B | |
Net Income Growth
| +74.08% | +13.58% | -41.45% | -7.63% | |
Net Margin Growth
| +21.55% | +22.91% | +17.67% | +16.33% | |
Extraordinaries & Discontinued Operations
| - | - | 86.00M | 543.00M | - |
Discontinued Operations
| - | - | 86.00M | 543.00M | - |
Net Income After Extraordinaries
| 6.43B | 7.21B | 4.76B | 3.90B | |
Preferred Dividends
| - | 164.00M | 106.00M | 21.00M | |
Net Income Available to Common
| 6.27B | 7.10B | 4.74B | 3.90B | |
EPS (Basic)
| 8.7727 | 9.7959 | 6.4399 | 5.3338 | |
EPS (Basic) Growth
| +76.50% | +11.66% | -34.26% | -17.18% | |
Basic Shares Outstanding
| 714.60M | 725.10M | 736.50M | 731.00M | |
EPS (Diluted)
| 8.6143 | 9.6636 | 6.3827 | 5.2889 | |
EPS (Diluted) Growth
| +76.33% | +12.18% | -33.95% | -17.14% | |
Diluted Shares Outstanding
| 736.80M | 737.10M | 743.10M | 737.20M | |
EBITDA
| 10.22B | 10.92B | 7.45B | 7.54B | |
EBITDA Growth
| +67.87% | +6.86% | -31.82% | +1.22% | |
EBITDA Margin
| +34.69% | +34.70% | +31.16% | +31.56% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 255.783 | |
| Number of Ratings | 30 | Current Quarters Estimate | 1.755 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | 7.656 | |
| Last Quarter’s Earnings | 1.63 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 7.48 | Next Fiscal Year Estimate | 8.602 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 23 | 23 | 26 | 26 |
| Mean Estimate | 1.76 | 1.88 | 7.66 | 8.60 |
| High Estimates | 1.85 | 1.94 | 7.78 | 9.03 |
| Low Estimate | 1.63 | 1.76 | 7.57 | 8.20 |
| Coefficient of Variance | 3.06 | 2.49 | 0.81 | 2.24 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 23 | 22 | 19 |
| OVERWEIGHT | 3 | 3 | 3 |
| HOLD | 4 | 5 | 6 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Overweight |
SEC Filings for Danaher Corp. - DHR
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Danaher Corp. - DHR
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 6, 2025 | Robert Bradley Gray SVP Strategic Development | 6 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Julie Sawyer Montgomery Executive Vice President | 4,884 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $211.14 per share | 1,031,207.76 |
| Feb 26, 2025 | Jose-Carlos Gutiérrez-Ramos SVP, Chief Science Officer | 12,372 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $211.14 per share | 2,612,224.08 |
| Feb 26, 2025 | Georgeann F. Couchara SVP, Human Resources | 4,015 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $211.14 per share | 847,727.10 |
| Feb 26, 2025 | Christopher Paul Riley Executive Vice President | 11,149 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $211.14 per share | 2,353,999.86 |
| Feb 26, 2025 | Christopher M. Bouda VP, Chief Accounting Officer | 7,196 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $211.14 per share | 1,519,363.44 |
| Jul 17, 2024 | John T. Schwieters Director | 19,808 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $52.56 per share | 1,041,108.48 |
| Jul 17, 2024 | John T. Schwieters Director | 19,105 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $246.23 per share | 4,704,224.15 |
| Jul 17, 2024 | John T. Schwieters Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 17, 2024 | Elias A. Zerhouni Director | 37,483 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $52.56 per share | 1,970,106.48 |
| Jul 17, 2024 | Elias A. Zerhouni Director | 36,780 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $246.23 per share | 9,056,339.40 |
| Jul 17, 2024 | Elias A. Zerhouni Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 16, 2024 | Rainer M. Blair President & CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 16, 2024 | Rainer M. Blair President & CEO; Director | 121,921 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $62.85 per share | 7,662,734.85 |
| May 16, 2024 | Rainer M. Blair President & CEO; Director | 135,080 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $58.59 per share | 7,914,337.20 |
| May 16, 2024 | Rainer M. Blair President & CEO; Director | 115,995 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $255 per share | 29,578,725.00 |
| May 16, 2024 | Rainer M. Blair President & CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 14, 2024 | Matthew R. McGrew EVP & Chief Financial Officer | 29,407 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $253.08 per share | 7,442,323.56 |
| May 14, 2024 | Matthew R. McGrew EVP & Chief Financial Officer | 45,338 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $62.85 per share | 2,849,493.30 |
| May 14, 2024 | Matthew R. McGrew EVP & Chief Financial Officer | 38,650 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $58.48 per share | 2,260,252.00 |